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Introduction: Concurrent signal transduction inhibition with the
epidermal growth factor receptor (EGFR) inhibitor gefitinib and the
mammalian target-of-rapamycin inhibitor everolimus has been hy-
pothesized to result in enhanced antitumor activity in patients with
non-small cell lung cancer (NSCLC). This phase II trial assessed the
efficacy of the combination of gefitinib and everolimus in patients
with advanced NSCLC.
Methods: Two cohorts of 31 patients with measurable stage IIIB/IV
NSCLC were enrolled: (1) no prior chemotherapy and (2) previously
treated with cisplatin or carboplatin and docetaxel or pemetrexed.
All patients received daily everolimus 5 mg and gefitinib 250 mg.
Response was assessed after 1 month and then every 2 months.
Pretreatment tumor specimens were collected for mutation testing.
Results: Sixty-two patients were enrolled (median age: 66 years, 50%
women, 98% stage IV, all current/former smokers, and 85% adenocar-
cinoma). Partial responses were seen in 8 of 62 patients (response rate:
13%; 95% confidence interval: 5–21%); five responders had received
no prior chemotherapy. Three partial responders had an EGFR muta-
tion. Both patients with a KRAS (G12F) mutation responded. The
median time to progression was 4 months. Median overall survival was
12 months, 27 months for no prior chemotherapy patients, and 11
months for patients previously treated with chemotherapy.
Conclusions: The 13% partial response rate observed did not meet
the prespecified response threshold to pursue further study of the
combination of gefitinib and everolimus. The response rate in
patients with non-EGFR mutant tumors was 8%, likely reflecting
activity of everolimus. Further investigation of mammalian target-
of-rapamycin inhibitors in patients with NSCLC with KRAS G12F-
mutated tumors is warranted.
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The epidermal growth factor receptor (EGFR) pathway iscritical to some lung adenocarcinoma cells. The EGFR-
tyrosine kinase inhibitors (TKIs), gefitinib (Iressa, AstraZeneca,
USA) and erlotinib (Tarceva, Genentech, South San Francisco,
CA), have emerged as valuable treatments for some patients
with non-small cell lung cancer (NSCLC). Sensitivity to these
agents is largely conferred by activating mutations in the EGFR
tyrosine kinase domain1–3 with partial responses seen in 58 to
90% in patients with EGFR-mutant tumors.4,5
Unfortunately, the clinical benefit of the EGFR-TKIs is
limited both by primary and acquired resistance. Patients who
initially respond to EGFR TKIs develop acquired resistance
after a median time of approximately 12 months.6 KRAS
mutations occur in 15 to 30% of patients with NSCLC and are
associated with primary resistance to EGFR-TKIs.7–9 Evi-
dence also supports dysregulation of downstream apoptotic
pathways, such as the phosphoinositide 3-kinase (PI3K)/Akt/
phosphatase and tensin homolog (PTEN) pathway, as a pos-
sible mechanism for primary resistance.10,11
The mammalian target-of-rapamycin (mTOR) is a serine-
threonine kinase that is a downstream effector of the PI3K/Akt/
PTEN pathway and regulates cellular growth and proliferation.
Several lines of preclinical data suggested a role for mTOR
inhibitors in NSCLC.12–14 In phase II clinical trials in advanced
NSCLC, partial response rates to mTOR inhibitors range from 3
to 8%.15,16 To date, no biomarker predicting efficacy of mTOR
inhibitors in NSCLC has been validated.
Given the possible role of dysregulation of the PI3K/
Akt/PTEN/mTOR pathway in both primary and secondary
resistance to the EGFR-TKIs, we hypothesized that concur-
rent signal transduction inhibition with the EGFR-TKI, ge-
fitinib, and the mTOR inhibitor, everolimus (Afinitor, Novar-
tis, Switzerland), would result in improved antitumor activity
in patients with NSCLC. Enhanced antitumor activity of
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gefitinib would be of particular use in patients less likely to
benefit from EGFR TKIs such as smokers or patients with
KRAS-mutant tumors. The phase I portion of our phase I/II
clinical trial of gefitinib and everolimus was reported previ-
ously.17 The results of the phase II portion of this trial are
reported in this study. The objective of the phase II portion of
the study was to determine the major objective response rate
of the combination of daily gefitinib and everolimus in
patients with advanced NSCLC.
PATIENTS AND METHODS
Patient Eligibility
All patients had pathologically confirmed NSCLC and
stage IIIB (with malignant pleural or pericardial effusion), stage
IV, or recurrent disease. Eligibility requirements included
Karnofsky performance status 70% and measurable disease.
Unstained slides or a tissue block were also required for molec-
ular correlative studies. Patients were enrolled in two cohorts: no
prior chemotherapy for advanced NSCLC and previously treated
with one or more prior chemotherapy regimens that had in-
cluded (1) cisplatin or carboplatin and (2) docetaxel or pem-
etrexed. Laboratory parameters included white blood cell count
3000/l; hemoglobin 9 g/dl; platelet count 100,000/l;
total bilirubin 1.5  the upper limit of normal (ULN); aspar-
tate aminotransferase 1.5  ULN; and creatinine 1.5 
ULN or creatinine clearance 60 ml/min. Patients were ex-
cluded if they had unstable brain metastases, other active cancer,
or prior treatment with EGFR TKIs. This trial was reviewed and
approved by the Institutional Review Board of the Memorial
Sloan-Kettering Cancer Center.
Treatment
After obtaining informed consent, patients were treated
with gefitinib 250 mg daily and everolimus 5 mg daily as
determined in our earlier phase I study.17 Dose reduction of
everolimus to 2.5 mg daily was allowed for toxicity not
managed by optimal supportive care. Dose reduction of
gefitinib to 250 mg every other day was allowed for side
effects attributable to gefitinib. Dose interruption of both
everolimus and gefitinib for grade 3 or 4 toxicities was
allowed until resolution of the toxicity ( grade 1). For grade
3 or 4 skin toxicity, dose interruption of gefitinib only was
allowed with continuation of everolimus unless the toxicity
did not resolve within 1 week. For grade 3 or 4 dyslipidemia,
dose interruption of everolimus only was permitted. Patients
with grade 3 or 4 toxicities that did not resolve in 2 weeks
were removed from the study.
Evaluation/Assessment
During the first month of therapy, patients were as-
sessed weekly with a history, physical examination, perfor-
mance status evaluation, and toxicity assessment. A complete
blood count and comprehensive metabolic panel were per-
formed during the second and third week of treatment. After
the first month, patients were assessed, and blood work was
obtained on a monthly basis. All toxicities were graded using
National Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0. Patients had baseline computed
tomography scanning with reassessment in the fourth and
eighth week of therapy, then every 8 weeks thereafter. Tumor
response was determined using the Response Evaluation
Criteria in Solid Tumors.18
Biostatistics
A Simon two-stage design was used to test the null
hypothesis of a 10% response rate against the alternative of
25% response rate. Sixty-two patients were enrolled in two
31-patient cohorts. Each cohort was considered separately.
The first stage of each cohort enrolled 16 patients. If the
number of responses was fewer than two, the drug would be
considered inactive in that cohort and accrual would stop. If
two or more of 16 patients had an objective response, the
cohort was to be expanded to 31 patients. The combination of
gefitinib and everolimus would be considered worthy of
further evaluation if six or more of 31 patients (19%) in either
cohort had objective responses. This design has a 10% type I
error rate and 80% power. Time to progression was defined as
the time from the first dose of study drug to the first objective
documentation of tumor progression. Survival time was de-
fined as the time from study enrollment to the time of death.
Overall survival was estimated using the Kaplan-Meier
method.
Molecular Studies
Tumor samples were analyzed for mutations within
KRAS exon 2 and EGFR exons 19 and 21 using previously
described standard methods.3
RESULTS
Baseline Characteristics
Between May 2004 and April 2005, 10 patients were
enrolled in the phase I study. Two previously treated patients
from the phase I trial who met all requirements for this phase II
study and had received the identical doses and schedule of
gefitinib and everolimus were included. From July 2005 to
August 2008, 65 patients were enrolled. Only current or former
smokers enrolled in the study because of competing clinical
trials that preferentially enrolled never smokers. Three patients
never received treatment and were replaced. Thirty-one patients
had no prior chemotherapy for advanced NSCLC, and thirty-one
patients had received one or more prior chemotherapies. The
majority of patients had stage IV disease and adenocarcinoma
histology. Patient characteristics are outlined in Table 1.
Treatment
All 62 patients were treated with gefitinib 250 mg daily
and everolimus 5 mg daily. Patients remained on treatment
from 7 to 787 days (median 107  139 days).
Efficacy
All patients who received even a single dose of study
drug were included. Eight patients (8 of 62) had a confirmed
partial response for an overall response rate of 13% (95%
confidence interval [CI]: 5–21%). The median duration of
response for patients with a partial response was 10 months.
In the no prior chemotherapy cohort, five patients had a
partial response (Figure 1). Nineteen of 31 patients (61%)
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achieved disease stability lasting a median of 4 months. Seven of
31 (23%) had disease progression as the best response. The
median follow-up time was 16 months (range: 10–37 months).
In the cohort previously treated with chemotherapy, three
patients had a partial response (Figure 2). All three partial
responders had received cisplatin or carboplatin and docetaxel.
Seventeen of 31 (55%) achieved disease stability lasting a
median of 3 months. Eleven of 31 (35%) had disease progres-
sion as the best response. The median follow-up time was 7
months (range: 1–28 months). The distribution of tumor re-
sponses is shown in waterfall format in Figures 1 and 2.
The median time to progression for all patients was 4
months (range: 1–26). Median overall survival was 12
months for all patients. By cohort, the median overall survival
was 27 months for patients who had received no prior
chemotherapy and 11 months for patients previously treated
with chemotherapy. The 1-year survival was 59% for the no
prior chemotherapy patients and 39% for the previously
treated cohort (Figure 3).
Correlative Studies
EGFR (exons 19 and 21) mutation testing was performed
on 59 of 62 enrolled patients. KRAS mutation testing was
performed on 55 of 62 enrolled patients. One patient had
squamous histology, so mutation testing for EGFR and KRAS
was not performed. Tissue was not available for EGFRmutation
testing in two patients. Two patients were first found to have an
EGFRmutation, soKRAS testing was not performed. Tissue was
not available for KRAS testing in three patients; one patient had
tissue sent, but DNA could not be extracted. A total of three
patients (two with no prior chemotherapy and one previously
treated with chemotherapy) had an EGFR-activating mutation.
A total of 16 patients (nine with no prior chemotherapy and
seven previously treated) had a KRAS mutation for a KRAS
mutation rate of 29% (16 of 55 tested). The KRAS mutation
subtypes and distribution are shown in Table 1. Of the eight
partial responders, three patients had an EGFR-activating muta-
tion (exon 19 deletion). One patient with an EGFR mutation
who initially responded developed acquired resistance and dis-
ease progression and on rebiopsy was found to have a T790M
mutation. Five of eight partial responders did not have an EGFR
mutation for a response rate of 8% (5 of 59; 95% CI: 1–15%) in
the non-EGFRmutated population. Of the eight responders, two
patients had a KRAS mutation (both subtype G12F); both were
in the cohort previously untreated with chemotherapy. The
response rate in KRAS mutated patients was 13% (2 of 16; 95%
CI: 4–36%).
Toxicity
Table 2 lists the treatment-related adverse effects by
grade. Adverse effects are reported as the highest grades expe-
rienced by individual patients at any time on the trial. The most
frequent toxicities were rash, diarrhea, oral mucosal ulcerations,
and fatigue. The most common hematologic toxicity was lym-
phopenia. Most toxicities were grades 1 to 2 and easily man-
aged. Thirteen patients experienced nonhematologic treatment-
related toxicities  grade 3. One patient experienced grade 3
dyslipidemia. Seven patients (11%) required a dose reduction for
toxicity. Nineteen patients (31%) required a treatment interrup-
TABLE 1. Patient Characteristics
Characteristics
All
Patients
(n  62)
No Prior
Treatment
(n  31)
Prior
Treatment
(n  31)
Median age (range) 66 (40–86) 68 (43–77) 64 (40–80)
Gender
Female 31 (50%) 14 (45%) 17 (55%)
Karnofsky performance
status
90% 16 (26%) 6 (19%) 10 (32%)
80% 39 (63%) 22 (71%) 17 (55%)
70% 7 (11%) 3 (10%) 4 (13%)
Stage
IIIB (malignant
effusion)
1 (2%) 1 (3%) —
IV 61 (98%) 30 (97%) 31 (100%)
Recurrent disease 26 (42%) 16 (52%) 10 (32%)
Histology
Adenocarcinoma 53 (85%) 27 (87%) 26 (84%)
Squamous 3 (5%) 2 (6%) 1 (3%)
Non-small cell
carcinoma
6 (10%) 2 (6%) 4 (13%)
Smoking history
Former 59 (95%) 31 (100%) 28 (90%)
Current 3 (5%) — 3 (10%)
Mutation status
EGFR (n  59)
Exon 19 deletion 3 (5%) 2 (3%) 1 (2%)
L858R — — —
KRAS (n  55) 16 (29%) 9 (16%) 7 (13%)
G12A 2 1 1
G12V 2 — 2
G12D 2 1 1
G12F 2 2 —
G13D 1 1 —
G12C 7 4 3
Previous therapy (%)
Cisplatin — — 41%
Carboplatin — — 61%
Docetaxel — — 61%
Paclitaxel — — 32%
Pemetrexed — — 51%
Gemcitabine — — 22%
Vinorelbine — — 16%
Bevacizumab — — 32%
3 previous lines — — 19%
Subsequent chemotherapy
(%)
Platinum — 45% 6%
Taxanes — 38% 19%
Pemetrexed — 54% 19%
Gemcitabine — 48% 38%
Vinorelbine — 35% 38%
Mitomycin — 19% 22%
Bevacizumab — 29% 29%
Erlotinib — 9% 9%
Experimental agent — 9% 29%
Other — 9% —
No additional treatment 12% 12%
EGFR, epidermal growth factor receptor.
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tion for toxicity. Of the seven patients removed from the proto-
col because of drug-related toxicity, two patients were removed
for possible drug-related pulmonary toxicity manifesting as lung
infiltrates, cough, and dyspnea. In one patient, the pulmonary
toxicity was felt to be secondary to everolimus; in the second
patient, the pulmonary toxicity was attributed to either everoli-
mus or gefitinib. Two patients were removed for rash, two with
anorexia and fatigue, and one patient due to dry skin and
extremity pain.
There were 30 serious adverse events reported for 21
patients. Only one hospitalization was definitely related to the
study drugs (grade 3 diarrhea). Three patients died while on
study. One patient was hospitalized with new dyspnea,
cough, and fever. A computed tomography scan was suspi-
cious for pneumonia, but no specific infectious etiology was
identified. Although the most likely diagnosis was pneumo-
nia, pulmonary toxicity related to study drug(s) remained a
possibility. The patient was treated aggressively with broad-
FIGURE 1. Maximal percentage of
tumor reduction for target lesions
by RECIST in patients receiving
everolimus and gefitinib who had
no prior treatment with chemother-
apy. Bars without mutations repre-
sent patients whose tumors are wild
type for epidermal growth factor
receptor (EGFR) and KRAS.
FIGURE 2. Maximal percentage of tumor
reduction for target lesions by RECIST in
patients receiving everolimus and gefitinib
who had been previously treated with che-
motherapy. Bars without mutations repre-
sent patients whose tumors are wild type
for epidermal growth factor receptor (EGFR)
and KRAS.
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spectrum antibiotics and steroids but died 5 days later. One
patient was hospitalized for dyspnea and was found to have a
new left pleural effusion, new bilateral pulmonary emboli,
and disease progression. Study medications were stopped 15
days before death. At the last follow-up, he complained of
increasing pain, dyspnea, and weakness, and died 5 days
later. One patient was removed from study for disease pro-
gression 26 days before death. At the last follow-up, he had
grade 3 dyspnea and fatigue. He was enrolled in hospice care
and died 20 days later.
DISCUSSION
We report the results of a phase II trial of gefitinib and
everolimus in advanced NSCLC. The combination of ge-
TABLE 2. Toxicities with Gefitinib and Everolimus Occurring in 5% of Patients
Toxicity (n  62) Any Grade 1 Grade 2 Grade 3 Grade 4
Rash/desquamation 37 (60%) 17 (27%) 20 (32%) 0 (0%) 0 (0%)
Diarrhea 35 (56%) 28 (45%) 3 (5%) 4 (6%) 0 (0%)
Oral ulcerations 32 (52%) 11 (18%) 20 (32%) 1 (2%) 0 (0%)
Fatigue 28 (45%) 12 (19%) 12 (19%) 4 (6%) 0 (0%)
Nausea 19 (31%) 12 (19%) 6 (10%) 1 (2%) 0 (0%)
Epistaxis 18 (29%) 17 (27%) 1 (2%) 0 (0%) 0 (0%)
Lymphopenia 14 (23%) 0 (0%) 0 (0%) 13 (21%) 1 (2%)
Anorexia 11 (18%) 6 (10%) 4 (6%) 1 (2%) 0 (0%)
Dyspnea 10 (16%) 4 (6%) 4 (6%) 1 (2%) 1 (2%)
Neuropathy, sensory 8 (13%) 8 (13%) 0 (0%) 0 (0%) 0 (0%)
Thrombocytopenia 6 (10%) 2 (3%) 0 (0%) 4 (6%) 0 (0%)
Hyponatremia 6 (10%) 1 (2%) 0 (0%) 5 (8%) 0 (0%)
Vomiting 5 (8%) 5 (8%) 0 (0%) 0 (0%) 0 (0%)
Cough 5 (8%) 3 (5%) 2 (3%) 0 (0%) 0 (0%)
Anemia 5 (8%) 0 (0%) 1 (2%) 4 (6%) 0 (0%)
Elevated International
Normalized Ratio
5 (8%) 0 (0%) 0 (0%) 5 (8%) 0 (0%)
Hypophosphatemia 4 (6%) 0 (0%) 0 (0%) 4 (6%) 0 (0%)
Constipation 4 (6%) 3 (5%) 1 (2%) 0 (0%) 0 (0%)
Lower extremity edema 4 (6%) 3 (5%) 1 (2%) 0 (0%) 0 (0%)
Fever, nonneutropenic 4 (6%) 3 (5%) 1 (2%) 0 (0%) 0 (0%)
Pruritus 3 (5%) 2 (3%) 1 (2%) 0 (0%) 0 (0%)
Dry skin 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
Dry eye 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
Dysgeusia 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
Weight loss 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
Headache 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
Back pain 3 (5%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
FIGURE 3. Overall survival of pa-
tients with non-small cell lung can-
cer (NSCLC) receiving everolimus
and gefitinib with and without prior
chemotherapy.
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fitinib and everolimus had a partial response rate of 13%,
which did not meet the predetermined criteria of a 19%
response rate to declare the combination worthy of further
study. The long median overall survival in the cohort of
patients who had not received prior therapy underscores the
feasibility of enrolling patients with advanced NSCLC in
clinical trials as front-line therapy. The hypothesis of the
study that concurrent signal transduction inhibition with ge-
fitinib and everolimus would result in enhanced antitumor
activity was based on preclinical data showing a synergistic
antitumor effect on human lung cancer cells.19,20 However,
the efficacy of the combination of gefitinib and everolimus
seems to be similar to that seen with treatment with either
everolimus alone or gefitinib alone in unselected patients.15,21
One possible explanation for the lack of efficacy with the
combination of gefitinib and everolimus is activation of
another pathway(s) that drives tumor growth. Recent data
demonstrate that mTOR inhibition can lead to activation of the
mitogen-activated protein kinase (MAPK) and Akt path-
ways and that targeting these pathways enhanced mTOR
efficacy.19,22–25 Another possible explanation is the presence
of a coexisting mutation, such as a PIK3CA or PTEN muta-
tion, which could interfere with the efficacy of gefitinib and
everolimus. A PIK3CA mutation, which can occur concomi-
tantly with KRAS mutations,26–28 can lead to persistent activa-
tion of the PI3K/Akt pathway despite EGFR inhibition and has
been shown to confer resistance in vitro in gefitinib-sensitive
lung cancer cell lines.29 In this study, KRAS mutations occurred
in 29% of the samples tested, and the presence of a PIK3CA
mutation could represent a targetable resistance pathway.
PTEN-deficient cell lines have been shown to be associated with
resistance to EGFR inhibitors30,31 and a PTEN deficiency could
lead to activation of the PI3K/Akt pathway and mTOR resis-
tance by accumulation of phosphatidylinositol 3,4,5-triphos-
phate and persistent signaling through Akt/protein kinase B. In
future studies, comprehensive assessment of PI3K, AKT, MEK,
BRAF, and LKB should be performed but was not possible in
this study because of limitations of available tissue.
One especially valuable aspect of this trial is the avail-
ability of EGFR and KRAS mutation testing in the majority of
patients, which provides some insight into the mechanisms of
response. Excluding the three responders who had an EGFR
mutation where responses to gefitinib are expected, the re-
sponse rate was 8%. The results of a phase III randomized
trial comparing gefitinib with carboplatin and paclitaxel in
advanced NSCLC reported a response rate to gefitinib in
EGFR mutation-negative patients of 1%,32 suggesting that
our 8% response rate in patients with wild-type tumors likely
reflects the activity of everolimus or the combination of the
agents, perhaps through the presence of an EGFR mutation
undetectable by the study assay or an alternative molecular
target. One responder with an EGFR mutation subsequently
developed acquired resistance and was found to have a
second mutation, T790M, indicating that, in that patient, the
mutant EGFR was the therapeutic target.
Intriguingly, we observed 2 KRAS (G12F) mutations
among the eight responders. Although KRAS mutations are
common in NSCLC, the G12F mutation subtype represents
1% of the total KRAS mutations in lung cancer.33 Because
responses to gefitinib in tumors harboring KRAS mutations
are mechanistically unlikely and less than 1% in the litera-
ture, responses in the individuals whose tumors harbored a
G12F mutation are likely attributable to everolimus. We
observed a response rate of 13% in patients with KRAS-
mutated tumors. Whether response is more common in the
G12F variant or because of other coexistent sensitizing or
resistance mechanisms in KRAS mutant tumors is unclear but
is an area of active investigation. The use of mTOR inhibitors
in patients with a KRAS mutation, and perhaps specifically
KRAS (G12F) mutation, may represent a targeted therapy for
a subset of patients with lung adenocarcinomas. Preclinical
studies investigating mTOR inhibition on KRAS (G12F)-
mutated cell lines are being planned, and phase II clinical
trials of other mTOR inhibitors in patients with KRAS mutant
NSCLC are currently underway.
Pulmonary toxicity has been described for both gefitinib
and the mTOR inhibitors. Gefitinib-induced pulmonary toxicity
occurs in approximately 1% of patients and manifests as inter-
stitial lung disease or diffuse alveolar damage. Gefitinib pulmo-
nary toxicity typically presents as the acute onset of dyspnea
with cough and possibly a low-grade fever. Approximately one
third of cases are fatal.34 Consequently, gefitinib should be
discontinued permanently in any case of suspected pulmonary
toxicity. The rate of pulmonary toxicity related to mTOR inhib-
itors has been reported to be as high as 25 to 36%, with typical
radiographic findings including ground glass opacities and lung
consolidation.35,36 Unlike gefitinib pulmonary toxicity, patients
with mTOR pulmonary toxicity can be asymptomatic or have
mild symptoms, and treatment can often be continued with close
monitoring. In our study, two patients discontinued study ther-
apy due to concern for possible drug-related pulmonary toxicity.
One patient was believed to have everolimus lung toxicity and
the other to have gefitinib toxicity. Given the high risk of fatality
with gefitinib pulmonary toxicity, it was appropriate to remove
both patients from study as they had both been receiving ge-
fitinib. The patient suspected to have gefitinib pulmonary toxic-
ity died 5 days after discontinuation of therapy, underscoring the
importance of maintaining a heightened clinical suspicion for
gefitinib pulmonary toxicity. It is possible that the incidence of
mTOR pulmonary toxicity in our study is underreported because
the trial was not designed to capture radiographic findings other
than response, and patients may have had minimal or no symp-
toms that could have been reported (dyspnea 16% and cough
8%) but not recognized as drug toxicity.
One shortcoming of the trial design is that both gefitinib
and everolimus affect partially overlapping molecular path-
ways. It may be beneficial to design trials testing agents that
block different molecular pathways such as combination therapy
with an mTOR inhibitor and a MAPK inhibitor, MAPK/ERK
kinase inhibitor, or insulin-like growth factor receptor inhibitor
with or without EGFR inhibition. Another limitation of this
study is that the tissue was tested only for the two primary EGFR
mutations (exon 19 deletion, L858R) which could potentially
miss less common, drug-sensitizing EGFR mutations in up to
10% of patients. Furthermore, additional biomarker informa-
tion such as phospho-Akt, PTEN, or PIK3CA mutation status
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to provide insight into the in vivo effect of mTOR inhibition
and possible mechanisms of mTOR resistance was not inves-
tigated. Because currently there is no validated biomarker
predictive of response to mTOR inhibitors, additional molec-
ular studies beyond EGFR and KRAS mutation status were
not investigated. Identification of markers predictive of response
to mTOR inhibition would help to identify patients likely to
benefit from therapy and should be considered as part of future
clinical trials investigating mTOR-targeted agents.
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